SCHEMBL5043717

SCHEMBL5043717

COc1ccc(-c2nc(-c3cc(C(=O)O)c(C)n3CC(C)C)cs2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.53
ALDH1A1 P00352 4/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HPGD P15428 2/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
ATM Q13315 1/20 0.46
EIF4E P06730 6/20 0.45
KLKB1 P03952 1/20 0.43
CYP19A1 P11511 1/20 0.43
CDC25A P30304 2/20 0.42
CDC25B P30305 2/20 0.42
CDC25C P30307 1/20 0.42
DUSP3 P51452 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044164 0.89 KLKB1 (0.51) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5043851 0.88 SMN1; SMN2 (0.48) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5045711 0.88 KDM4E (0.55) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6471925 0.86 KDM4E (0.53) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5044535 0.86 ALDH1A1 (0.53) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6879060 0.86 KDM4E (0.53) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6881059 0.86 EIF4E (0.50) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5039541 0.85 KDM4E (0.52) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6882640 0.85 KDM4E (0.52) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6882607 0.85 KDM4E (0.49) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KDM4E 2916/4885ALDH1A1 959/4885NPC1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.